Mucormycosis
📧 Sign up to get email alerts when something new happens for Mucormycosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-12EMA Authorised: Posaconazole Accord (posaconazole) — Accord Healthcare S.L.U.
Authorised status for Posaconazole Accord, MAH Accord Healthcare S.L.U., in the therapeutic area of mycoses.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
A post-marketing surveillance study of Cresemba (isavuconazole) in Korea has completed, evaluating safety and usage in patients with aspergi…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
A single-center comparative analysis from China assessing how the burden of mucormycosis evolves in patients with hematologic malignancies d…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment [Phase 2]
A Phase 2 pilot trial of high-dose liposomal amphotericin B for initial treatment of mucormycosis has completed.
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Biomarkers for Invasive Mucormycosis
A clinical trial from University Hospital Lille is researching biomarkers for invasive mucormycosis and is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
This completed trial evaluated whether Paxlovid (nirmatrelvir/ritonavir) influenced healthcare utilization in people with pre-existing condi…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Immunomonitoring of Mold Invasive Infections
A clinical trial evaluating immunomonitoring of mold invasive fungal infections is currently recruiting, sponsored by Assistance Publique - …
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
This clinical trial compares amphotericin B versus isavuconazole for mucormycosis to evaluate comparative efficacy and safety; the study is …
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
A clinical trial is evaluating the efficacy and safety of a combination therapy of liposomal amphotericin B with posaconazole or isavuconazo…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
Clinical trial update for the MUCOR-ADVANCE P01 project evaluating mucormycosis; the study is not yet recruiting according to ClinicalTrials…
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: Isavuconazole in Critically Ill Patients: Efficacy and Safety
Clinical trial update for isavuconazole in critically ill patients indicating the study is not yet recruiting; conditions include invasive a…
-
FDA approval · 2025-06-02FDA Approved: AMPHOTERICIN B — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original application for Amphotericin B as a generic drug by Heritage Pharmaceuticals (Avet) to treat serious systemic funga…
-
FDA approval · 2025-03-24FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for CRESEMBA (isavuconazonium sulfate) filed by Astellas Pharma US, Inc.
-
FDA approval · 2025-03-13FDA Approved: POSACONAZOLE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for posaconazole from Mylan Institutional LLC, updating the approval for the generic product.
-
EMA approval · 2025-01-21EMA Authorised: Posaconazole AHCL (posaconazole) — Accord Healthcare S.L.U.
EMA authorised Posaconazole AHCL by Accord Healthcare S.L.U. for mycoses. The EU marketing authorization was granted on 16 January 2025.
-
FDA approval · 2024-12-23FDA Approved: POSACONAZOLE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' posaconazole under an Original Application (ANDA), marking a generic approval for this antifungal.
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children [NA]
An ongoing pediatric study evaluates therapeutic drug monitoring and pharmacokinetics of isavuconazole in children with invasive aspergillos…
-
CLINICAL_TRIALS research · 2024-08-15Clinical Trial Update: Rehabilitation With an Obturator in Maxillary Defects
Clinical trial update on rehabilitation with an obturator for maxillary defects in mucormycosis patients; the study is currently active but …
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial update focusing on post-COVID-19 rhinocerebral mucormycosis in Egypt.
-
FDA approval · 2023-08-28FDA Approved: POSACONAZOLE — Original Application (i3 Pharmaceuticals, LLC)
FDA approved an original application for posaconazole from i3 Pharmaceuticals, LLC (generic posaconazole).
-
FDA approval · 2022-11-17FDA Approved: AMPHOTERICIN B — Original Application (Eugia US LLC)
FDA approved the original ANDA for Amphotericin B from Eugia US LLC, authorizing a generic Amphotericin B product.
-
FDA approval · 2022-07-28FDA Approved: POSACONAZOLE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for posaconazole delayed-release (POSACONAZOLE DELAYED-RELEASE) from Chartwell RX, LLC, updating its…
-
FDA approval · 2022-05-25FDA Approved: POSACONAZOLE — Original Application (Par Health USA, LLC)
FDA approved the original application for posaconazole (generic) by Par Health USA, LLC, marking the availability of a generic posaconazole …
-
FDA approval · 2022-02-17FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for CRESEMBA (isavuconazonium sulfate) submitted by Astellas Pharma US, expanding the approval throu…
-
FDA approval · 2022-02-17FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Cresemba (isavuconazonium sulfate) filed by Astellas Pharma US, expanding its approved use.